Vertex Pharmaceuticals Incorporated (VRTX)
-NasdaqGS 79.49 
1.60(2.05%) May 17, 4:00PM EDT|After Hours
:
79.49 0.00 (0.00%) May 17, 4:13PM EDT
| Prev Close: | 77.89 |
|---|
| Open: | 78.72 |
|---|
| Bid: | 75.93 x 200 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 93.02 |
|---|
| Beta: | 0.32 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 77.69 - 79.54 |
|---|
| 52wk Range: | 38.44 - 87.47 |
|---|
| Volume: | 2,622,604 |
|---|
| Avg Vol (3m): | 2,522,570 |
|---|
| Market Cap: | 17.38B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Bypassing Biotechs and Focusing on the Overlooked Medical Device Space: An Expert Portfolio Manager Discusses His Contrarian Approach to InvestingWall Street Transcript(Fri, May 17)
- InPlay: Vertex Pharm calls for redemption of $400 mln of its 3.35% Convertible Senior Subordinated Notes due 2015Briefing.com(Fri, May 17)
- Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015Business Wire(Fri, May 17)
- VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Triggering Events That Accelerate or Increase a Direct FinancialEDGAR Online(Fri, May 17)
- Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Laggardat TheStreet(Thu, May 16)
- A Fundamental, Bottom-Up Approach to Investing in Health Care: Portfolio Manager Finny Kuruvilla Discusses His Strategies with The Wall Street TranscriptWall Street Transcript(Thu, May 16)
- 2 Scariest Dividend Stocks in Health Careat Motley Fool(Thu, May 16)
- 3 Stocks Underperforming Today In The Drugs Industryat TheStreet(Wed, May 15)
- Racing Toward the Next Hepatitis C Drug Approvalat Motley Fool(Wed, May 15)
- VERTEX PHARMACEUTICALS INC / MA FinancialsEDGAR Online Financials(Tue, May 14)
- This Stock Deserved Its Sudden Upswingat Seeking Alpha(Mon, May 13)
- 3 Investment Strategy Lessons From Vertex's Successat Motley Fool(Sat, May 11)
- Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor ConferencesBusiness Wire(Thu, May 9)
- Did This Stock Deserve This Sudden Upward Swing?at Motley Fool(Thu, May 9)
- Vertex Debt Conversion Is Not Bad For Shareholdersat Seeking Alpha(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 12.02 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.06 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.18 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | -5.82 |
|---|
Business Summary
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases.
View More